Dainippon options rights to SanBio's stroke candidate SB623; exercised; terminated
SanBio Inc. (neural stem cell medicines) has given Dainippon Sumitomo Pharma Co. Ltd., the drug and food products division of Sumitomo Chemical Co., an option to license exclusive US and Canadian development and marketing rights to its lead candidate SB623, which is undergoing preclinical tests for disabilities caused by stroke.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com